drugset / Trial / NCT05263921

Relative Bioavailability Study of PF-07321332/Ritonavir Oral Powder Relative to the Commercial Tablets in Healthy Participants

NCT05263921

Phase 1 Completed 12 enrolled Pfizer
RandomizedCrossoverOpen-labelBasic science

Summary

The purpose of this study is to estimate the relative bioavailability of PF-07321332/ritonavir oral powder relative to the commercial tablet formulation under fasted condition in healthy adult participants. The study will also assess the effect of 3 different food vehicles on the relative bioavailability of the PF-07321332/ritonavir oral powder formulation as well as the safety, tolerability, and palatability of PF-07321332/ritonavir oral powder in healthy adult participants.

Timeline

Start
2022-03-10
Primary completion
2022-05-19
Completion
2022-05-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Nirmatrelvir Small molecule Oral
Subject Ritonavir Other / unclassified Oral

Indications

No indication recorded.